var data={"title":"Metoclopramide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metoclopramide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6570?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">see &quot;Metoclopramide: Drug information&quot;</a> and <a href=\"topic.htm?path=metoclopramide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metoclopramide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8117624\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Tardive dyskinesia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. There is no known treatment for tardive dyskinesia. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Discontinue metoclopramide in patients who develop signs or symptoms of tardive dyskinesia. In some patients, symptoms lessen or resolve after metoclopramide is stopped. Avoid treatment with metoclopramide for longer than 12 weeks because of the increased risk of developing tardive dyskinesia with longer-term use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195600\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Metozolv ODT [DSC];</li>\n      <li>Reglan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195601\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Metoclopramide Hydrochloride Injection;</li>\n      <li>Metoclopramide Omega;</li>\n      <li>Metonia</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060336\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Prokinetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443886\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Gastroesophageal reflux:</b> Limited data available: Oral, IM, IV: Usual dose: 0.1 mg/kg/dose every 6 hours (Avery, 1994; Kimball, 2001); higher doses of 0.15 mg/kg/dose have been reported in a pharmacokinetic study of 10 preterm neonates (PMA: 31 to 40 weeks) (Kearns, 1998).  In a small case series of previous VLBW (n=6; GA: 26 to 35 weeks; birth weight: 790 to 1040 g; mean PNA at treatment: 35 days), a lower dose of 0.033 mg/kg every 8 hours was reported effective in all patients (Sankaran, 1982). Doses &gt;0.15 mg/kg may increase potential for adverse effects due to excessive serum concentrations (Kearns, 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060329\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">see &quot;Metoclopramide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postpyloric feeding tube placement (short bowel intubation):</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient age: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;6 years: 0.1 mg/kg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">6 to 14 years: 2.5 to 5 mg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;14 years: 10 mg as a single dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux:</b> Limited data available; efficacy results variable (Vandenplas, 2009): <b>Note:</b> NASPGHAN/ESPGHAN guidelines do not recommend metoclopramide for routine treatment of GERD; evaluate risk:benefit prior to use (Vandenplas, 2009): Infants, Children, and Adolescents: Oral: 0.1 to 0.2 mg/kg/dose every 6 to 8 hours; maximum dose: 10 mg (Chicella, 2005; Forbes, 1986; Rode, 1987; Tolia, 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative nausea and vomiting; prevention:</b> Limited data available; optimal dose not established; efficacy results variable: <b>Note:</b> Guidelines discourage use of metoclopramide; considered ineffective (Gan, 2007): Children and Adolescents: IV: 0.1 to 0.5 mg/kg/dose as a single dose administered after induction or on arrival to PACU; maximum dose: 10 mg/dose (Ferrari, 1992; Furst, 1994; Henzi, 1999; Lin, 1992) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting (CINV), prevention:</b> Limited data available; optimal dose not established; efficacy results variable. <b>Note:</b> Doses required to prevent CINV are high and should not be used first-line due to increased risk of extrapyramidal symptoms (acute dystonic reactions); concurrent administration of diphenhydramine or benztropine is recommended to prevent drug-induced adverse effects (Dupuis, 2013; Roila, 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">POGO Guidelines (Dupuis, 2013): Infants, Children and Adolescents: <b>Note:</b> For use in patients in whom corticosteroids are contraindicated; use in combination with 5-HT<sub>3</sub> receptor antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Initial dose: IV: 1 mg/kg as a single dose prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Subsequent doses: Oral: 0.0375 mg/kg/dose every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Children and Adolescents: IV: 1 to 2 mg/kg/dose prior to and then every 2 to 4 hours up to every 6 hours following chemotherapy;  maximum: 5 doses/day (Roila, 1998; Terrin, 1984); another trial administered 2 mg/kg when chemotherapy was started followed by 2 mg/kg/dose 2, 6, and 12 hours later (Marshall, 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetic gastroparesis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 10 mg up to 4 times daily 30 minutes before meals and at bedtime for 2 to 8 weeks. Treatment &gt;12 weeks is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV (for severe symptoms): 10 mg over 1 to 2 minutes; 10 days of IV therapy may be necessary before symptoms are controlled to allow transition to oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced emesis prophylaxis:</b> IV: 1 to 2 mg/kg 30 minutes before chemotherapy and repeated every 2 hours for 2 doses, then every 3 hours for 3 doses (manufacturer's labeling); pretreatment with diphenhydramine will decrease risk of extrapyramidal reactions</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> <b>Note:</b> Metoclopramide is considered an antiemetic with a low therapeutic index; use is generally reserved for agents with low emetogenic potential or in patients intolerant/refractory to first-line antiemetics.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Low-risk chemotherapy:</i> IV, Oral: 10 to 40 mg prior to chemotherapy dose, then every 4 to 6 hours as needed (NCCN Antiemesis guidelines, v.1.2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Breakthrough treatment:</i> IV, Oral: 10 to 40 mg every 4 to 6 hours (NCCN Antiemesis guidelines, v.1.2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Delayed-emesis prophylaxis:</i> Oral: 20 to 40 mg (or 0.5 mg/kg/dose) 2 to 4 times daily for 3 to 4 days (in combination with dexamethasone (ASCO guidelines [Kris, 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Refractory or intolerant to antiemetics with a higher therapeutic index (Hesketh, 2008):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 1 to 2 mg/kg/dose before chemotherapy and repeat 2 hours after chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 0.5 mg/kg every 6 hours on days 2 to 4</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroesophageal reflux:</b> Oral: 10 to15 mg up to 4 times daily 30 minutes before meals or food and at bedtime; single doses of 20 mg are occasionally needed prior to provoking situations. Treatment &gt;12 weeks is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative nausea and vomiting prophylaxis:</b> IM, IV: 10 to 20 mg near end of surgery. <b>Note:</b> Guidelines discourage use of 10 mg metoclopramide as being ineffective (Gan, 2007); comparative study indicates higher dose (20 mg) may be efficacious (Quaynor, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postpyloric feeding tube placement, radiological exam:</b> IV: 10 mg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff, 2007).<b> Note:</b> Renally adjusted dose recommendations are based on doses of 0.1 to 0.2 mg/kg/dose every 6 to 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Administer 25% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;40 mL/minute: Administer 50% of recommended dose </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Not dialyzable (0% to 5%); supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, metoclopramide has been used safely in patients with advanced liver disease with normal renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195570\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (10 mL, 473 mL); 10 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reglan: 5 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Reglan: 10 mg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metozolv ODT: 5 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195554\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8083407\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metoclopramide oral solution: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM244086.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68UB3sXUE3glQjEZuI58rBVw==&amp;TOPIC_ID=12602\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM244086.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metozolv ODT: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM187064.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQo4kAbL5TYxyavRm7IY9l4Q==&amp;TOPIC_ID=12602\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM187064.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reglan injection: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM176362.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQN7r4+OcDEcv6bJLefhtiDA==&amp;TOPIC_ID=12602\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM176362.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reglan tablet: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM235574.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68aJQyg8gZ9p8gvETRU3w7hQ==&amp;TOPIC_ID=12602\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM235574.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060340\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally disintegrating tablets: Administer on an empty stomach at least 30 minutes prior to food. Do not remove from packaging until time of administration. If tablet breaks or crumbles while handling, discard and remove new tablet. Using dry hands, place tablet on tongue and allow to dissolve. Swallow with saliva.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution, tablet: Administer 30 minutes before meals and at bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: May be administered  IM</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Note:</b> Rapid IV administration is associated with a transient but intense feeling of anxiety and restlessness, followed by drowsiness</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV push: For doses &le;10 mg may be administered undiluted (5 mg/mL) by direct IV push over 1 to 2 minutes.  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV infusion: For higher doses (&gt;10 mg), dilute dose prior to use and administer over at least 15 minutes  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195592\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. Injection is photosensitive and should be protected from light during storage; parenteral admixtures in D5W, D5<sub><sup>1</sup>/<sub>2</sub></sub>NS, NS, LR, or Ringer's injection are stable for up to 24 hours after preparation at normal light conditions or up to 48 hours if protected from light. When mixed with NS, can be stored frozen for up to 4 weeks; metoclopramide is degraded when admixed and frozen with D<sub>5</sub>W.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution/orally disintegrating tablet/tablet: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light. Do not freeze oral solution. Keep orally disintegrating tablet in original packaging until just prior to use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060339\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (orally disintegrating tablet [Metizolv ODT], solution, tablet): Symptomatic treatment of gastroesophageal reflux; diabetic gastroparesis (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Symptomatic treatment of acute and recurrent diabetic gastroparesis; prevention of nausea and vomiting associated with chemotherapy; prevention of postoperative nausea and vomiting (All indications: FDA approved in adults); facilitates intubation of the small intestine (postpyloric placement of enteral feeding tube) (FDA approved in pediatric patients [age not specified] and adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195664\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Metoclopramide may be confused with metOLazone, metoprolol, metroNIDAZOLE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Reglan may be confused with Megace, Regonol, Renagel, Regitine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Metoclopramide is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless used for the treatment of gastroparesis) due to its potential for causing extrapyramidal effects, including tardive dyskinesia; these risks may be increased in frail older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195661\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrioventricular block, bradycardia, cardiac failure, flushing (following high IV doses), hypertension, hypotension, supraventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Akathisia, confusion, depression, dizziness, drowsiness (dose related), drug-induced Parkinson's disease, dystonic reaction (dose and age related), fatigue, hallucination (rare), headache, insomnia, lassitude, neuroleptic malignant syndrome (rare), restlessness, seizure, somnolence, suicidal ideation, tardive dyskinesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, fluid retention, galactorrhea, gynecomastia, hyperprolactinemia, porphyria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, urinary frequency, urinary incontinence</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, leukopenia, methemoglobinemia, neutropenia, sulfhemoglobinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema (rare), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Laryngospasm (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, laryngeal edema (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195578\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, laryngeal and glossal angioedema, bronchospasm) to metoclopramide or any component of the formulation; situations where stimulation of gastrointestinal (GI) motility may be dangerous, including mechanical GI obstruction, perforation, or hemorrhage (except when used prior to endoscopy for evaluation of acute upper GI bleeding [Barkun 2010]); pheochromocytoma or other catecholamine-releasing paragangliomas; seizure disorder (eg, epilepsy); history of tardive dyskinesia or dystonic reaction to metoclopramide; concomitant use with other agents likely to increase extrapyramidal reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Infants &lt;1 year of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195558\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Depression has occurred (in patients with and without a history of depression); symptoms have included suicidal ideation and suicide; avoid use in patients with a history of depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extrapyramidal symptoms (EPS): May cause extrapyramidal symptoms, generally manifested as acute dystonic reactions within the initial 24 to 48 hours of use at the usual adult dose (30 to 40 mg/day). Risk of these reactions is increased at higher than recommended doses, and in patients &lt;30 years of age. Symptoms may include involuntary limb movements, facial grimacing, torticollis, oculogyric crisis, rhythmic tongue protrusion, bulbar type speech, trismus, or dystonic reactions resembling tetanus. May also rarely present as stridor and dyspnea (may be due to laryngospasm). Dystonic symptoms may be managed with IM diphenhydramine or benztropine. Pseudoparkinsonism (eg, bradykinesia, tremor, cogwheel rigidity, mask-like facies) may also occur (usually within first 6 months of therapy but also after longer periods) and is generally reversible within 2 to 3 months following discontinuation. Motor restlessness (eg, anxiety, agitation, jitteriness, insomnia) may occur; if symptoms resolve, consider restarting at a lower dosage. Avoid metoclopramide in patients receiving other drugs that are likely to cause EPS (eg, antipsychotics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperprolactinemia: Metoclopramide elevates prolactin levels. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported. Hyperprolactinemia may potentially stimulate prolactin-dependent breast cancer. However, some clinical studies and epidemiology studies have not shown an association between administration of dopamine D<sub>2</sub> receptor antagonists and tumorigenesis in humans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: May elevate blood pressure; avoid use in patients with hypertension (IV administration was shown to release catecholamines). There are reports of hypertensive crises in patients with undiagnosed pheochromocytoma; use is contraindicated in patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Discontinue therapy in any patient with a rapid rise in blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: Use may be associated with neuroleptic malignant syndrome (NMS); may be fatal. Monitor for manifestations of NMS, which include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac arrhythmias); additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure. Discontinue immediately if signs/symptoms of NMS appear and begin intensive symptomatic management and monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proarrhythmic effects: Metoclopramide has been known to cause sinus arrest (usually with rapid IV administration or higher doses) (Bentsen 2002; Malkoff 1995). The torsadogenic potential for metoclopramide is considered to be low (Claassen 2005). Based on case reports, however, metoclopramide may cause QT prolongation and torsades de pointes in certain individuals (eg, heart failure patients with renal impairment) (Siddique 2009). There is data in healthy male volunteers to show that metoclopramide actually shortens the QT interval while at the same time increasing QT variance (Ellidokuz 2003). No human data other than case reports, however, has demonstrated a consistent QT prolonging effect with metoclopramide nor is there any substantiated evidence to show a direct association with the development of torsades de pointes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tardive dyskinesia: <b>[US Boxed Warning]: May cause tardive dyskinesia, a serious movement disorder that is often irreversible with no known treatment; the risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. Discontinue metoclopramide in patients who develop signs/symptoms of tardive dyskinesia; in some patients, symptoms may lessen or resolve after metoclopramide is stopped. Avoid treatment with metoclopramide for longer than 12 weeks because of the increased risk of developing tardive dyskinesia with longer-term use.</b> Avoid metoclopramide in patients receiving other drugs that are likely to cause tardive dyskinesia (eg, antipsychotics). Tardive dyskinesia is characterized by disfiguring involuntary movements of the face, tongue, and sometimes of the trunk and/or extremities; movements may be choreoathetotic in appearance. Metoclopramide may mask underlying tardive disease by suppressing or partially suppressing tardive dyskinesia signs; the effect of this symptomatic suppression upon the long-term course of tardive dyskinesia is unknown. The risk of developing tardive dyskinesia is increased in the elderly, especially elderly women, and diabetics, although it is not possible to predict which patients will develop tardive dyskinesia. Discontinue metoclopramide immediately in patients who develop signs/symptoms of tardive dyskinesia. There is no known effective treatment for established cases of tardive dyskinesia, although in some patients, tardive dyskinesia may remit (partially or completely) within several weeks to months after metoclopramide is withdrawn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure and concomitant renal impairment; may be at risk for development of QT prolongation and torsades de pointes (Siddique 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Edematous conditions: Use with caution in patients who are at risk of fluid overload (HF, cirrhosis). Metoclopramide causes a transient increase in serum aldosterone and increases the risk for fluid retention and volume overload. Discontinue if adverse events or signs/symptoms appear.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with moderate to severe hepatic impairment; risk of adverse reactions may be increased due to increased systemic exposure; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nicotinamide adenine dinucleotide hydrogen (NADH)-cytochrome b5 reductase deficiency: Patients with NADH-cytochrome b5 reductase deficiency are at increased risk of methemoglobinemia and/or sulfhemoglobinemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Symptoms of Parkinson disease may be exacerbated; avoid use in patients with Parkinson disease and other patients being treated with antiparkinsonian drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with moderate to severe renal impairment; risk of adverse reactions may be increased due to increased systemic exposure; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical anastomosis/closure: Use with caution following surgical anastomosis/closure; promotility agents may theoretically increase pressure in suture lines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2D6 poor metabolizers: Elimination of metoclopramide may be slowed possibly increasing the risk of dystonic and other adverse reactions; dosage reduction recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Risk of tardive dyskinesia may be increased in elderly, especially in elderly women.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not recommended for use (oral formulation) due to increased risk of tardive dyskinesia and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates (neonates may have decreased levels of NADH-cytochrome b5 reductase, which increases the risk of methemoglobinemia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195649\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195563\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12602&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Metoclopramide may diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Metoclopramide may enhance the adverse/toxic effect of Antipsychotic Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atovaquone: Metoclopramide may decrease the serum concentration of Atovaquone.  Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Metoclopramide may increase the absorption of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deutetrabenazine: May enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk for akathisia, parkinsonism, or neuroleptic malignant syndrome may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the adverse/toxic effect of Metoclopramide.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Benzamide Derivatives may enhance the adverse/toxic effect of Levosulpiride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Metoclopramide. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with metyrosine for development of extrapyramidal symptoms.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Metoclopramide may decrease the serum concentration of Posaconazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promethazine: Metoclopramide may enhance the adverse/toxic effect of Promethazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: Metoclopramide may diminish the therapeutic effect of Quinagolide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the adverse/toxic effect of Metoclopramide. Specifically, the risk of extrapyramidal adverse reactions  may be increased with this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Metoclopramide may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.<b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: Metoclopramide may enhance the adverse/toxic effect of Serotonin/Norepinephrine Reuptake Inhibitors.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with serotonin/norepinephrine reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrabenazine: Metoclopramide may enhance the adverse/toxic effect of Tetrabenazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopental: Metoclopramide may enhance the therapeutic effect of Thiopental.  Management: Consider thiopental dose reduction when used concomitantly with metoclopramide. Monitor patient response to treatment closely if using this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Metoclopramide may enhance the adverse/toxic effect of Tricyclic Antidepressants.  Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimetazidine: Metoclopramide may enhance the adverse/toxic effect of Trimetazidine. Specifically, the risk of extrapyramidal symptoms may be enhanced. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195566\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195581\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Metoclopramide crosses the placenta and can be detected in cord blood and amniotic fluid (Arvela 1983; Bylsma-Howell 1983). Available evidence suggests safe use during pregnancy (ACOG 2015; Berkovitch 2002; Matok 2009; S&oslash;rensen 2000). Evidence related to the efficacy for the treatment of nausea and vomiting of pregnancy is limited (ACOG 2015; Arsenault 2002); metoclopramide may be used for prophylaxis of nausea and vomiting associated with cesarean delivery (ASA 2016; Smith 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060335\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure and heart rate (when rapid IV administration is used); dystonic reactions, agitation, and confusion </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195557\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks dopamine receptors and (when given in higher doses) also blocks serotonin receptors in chemoreceptor trigger zone of the CNS; enhances the response to acetylcholine of tissue in upper GI tract causing enhanced motility and accelerated gastric emptying without stimulating gastric, biliary, or pancreatic secretions; increases lower esophageal sphincter tone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195577\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 30 to 60 minutes; IV: 1 to 3 minutes; IM: 10 to 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Therapeutic: 1 to 2 hours, regardless of route </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid, well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>:  Neonates, PMA 31 to 40 weeks: 6.94 L/kg (Kearns 1998); Infants: 4.4 L/kg; Children: 3 L/kg; Adults: ~3.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 80 &plusmn; 15.5% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: Neonates, PMA 31 to 40 weeks: 5.4 hours (Kearns, 1998); Infants: 4.15 hours (range: 2.23 to 10.3 hours) (Kearns 1988); Children: ~4 hours (range: 2 to 12.5 hours); half-life and clearance may be dose-dependent; Adults: 5 to 6 hours (may be dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Neonates, PMA 31 to 40 weeks: 2.45 hours (Kearns, 1998); Infants: 2.2 hours; Adults: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~85%); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195580\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Metoclopramide HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (2 mL): $0.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Metoclopramide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (10 mL): $0.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Metoclopramide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (10): $94.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (10): $94.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Metoclopramide HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $32.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $27.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Reglan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $354.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $354.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195583\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Afipran (NO);</li>\n      <li>Ametic (ZA);</li>\n      <li>Anausin (FR);</li>\n      <li>Balon (TW);</li>\n      <li>Carnotprim (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Ceolat (AT);</li>\n      <li>Cerucal (DE, EE, HU, LV);</li>\n      <li>Clomitene (PH);</li>\n      <li>Clopamon (ZA, ZW);</li>\n      <li>Cloperan (MT);</li>\n      <li>Clopram (BF, BJ, CI, ET, GH, GM, GN, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Cynovit (ET);</li>\n      <li>Dibertil (BE, LU);</li>\n      <li>Dirpasid (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>DO-Spertine (ET);</li>\n      <li>Donmet (LK);</li>\n      <li>Elitan (MT, TR, VN);</li>\n      <li>Emeliv (SG);</li>\n      <li>Emperal (DK);</li>\n      <li>Enakur (ID);</li>\n      <li>Enzimar (CO);</li>\n      <li>Fluccil (BR);</li>\n      <li>Gastro-Timelets (LU);</li>\n      <li>Gastrobi S.R. (KR);</li>\n      <li>Gastronerton (DE, LU);</li>\n      <li>Gastrosil (CH, DE, LU, PH);</li>\n      <li>Imperan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PY, SA, SY, TW, YE);</li>\n      <li>Itan (CL);</li>\n      <li>Legir (UY);</li>\n      <li>Macperan (KR);</li>\n      <li>Malon (MY);</li>\n      <li>Manosil (TH);</li>\n      <li>Maril (HK, SG, TH);</li>\n      <li>Maxeron (IN);</li>\n      <li>Maxocol (BD);</li>\n      <li>Maxolon (AE, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, GB, GH, GM, GN, GY, IE, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, SA, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>MCP-Beta Tropfen (DE);</li>\n      <li>MCP-ratiopharm (LU);</li>\n      <li>Meclomid (BD, MX);</li>\n      <li>Meclopram (ET);</li>\n      <li>Meclopstad (VN);</li>\n      <li>Mepamide (TH);</li>\n      <li>Metamide (NZ);</li>\n      <li>Metlazel (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Metoclamid (LU);</li>\n      <li>Metoclopramide-Eurogenerics (LU);</li>\n      <li>Metoclox (EC);</li>\n      <li>Metopram (FI);</li>\n      <li>Metovit (LK);</li>\n      <li>Metsil (PH);</li>\n      <li>Migen (BD);</li>\n      <li>Movain (BD);</li>\n      <li>Movistal (LU);</li>\n      <li>Nausil (TH);</li>\n      <li>Nilatika (ID);</li>\n      <li>Norvom (ID);</li>\n      <li>Nutramid (BD);</li>\n      <li>Opram (ID);</li>\n      <li>Paspertin (HU);</li>\n      <li>Perinorm (ET, IN, LK, RU, ZA);</li>\n      <li>Perone (TW);</li>\n      <li>Pharmyork (GR);</li>\n      <li>Piralen (ID);</li>\n      <li>Plasil (AE, BF, BH, BJ, BR, CI, CO, CR, CY, DO, EG, ET, GH, GM, GN, GT, HN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, OM, PA, PY, QA, SA, SC, SD, SL, SN, SV, SY, TH, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Polcotec (MX);</li>\n      <li>Pramidin (PL);</li>\n      <li>Pramin (AU, IL, TW);</li>\n      <li>Premosan (AE, BH, ET, KW, QA, SA);</li>\n      <li>Primperan (AE, AT, BE, BF, BH, BJ, CH, CI, CO, CR, CY, CZ, DK, DO, EE, EG, ES, ET, FI, FR, GH, GM, GN, GR, GT, HK, HN, JO, JP, KE, KW, LB, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, PA, PE, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SV, TN, TR, TW, TZ, UG, VE, VN, ZM, ZW);</li>\n      <li>Primperil (AR);</li>\n      <li>Prinparl (JP);</li>\n      <li>Prokinyl (LU);</li>\n      <li>Prowel (TW);</li>\n      <li>Pulin (MY, SG);</li>\n      <li>Regelan (PK);</li>\n      <li>Reglan (BG, HR, IN, SI);</li>\n      <li>Reglomar (PH);</li>\n      <li>Regurg (ET);</li>\n      <li>Reliveran (AR);</li>\n      <li>Remetin (LK);</li>\n      <li>Riamide (AE, QA);</li>\n      <li>Setin (ZA);</li>\n      <li>Sotatic-10 (ID);</li>\n      <li>Tricil (PY);</li>\n      <li>Tserukal (UA);</li>\n      <li>Vertivom (ID);</li>\n      <li>Vitamet (PH);</li>\n      <li>Vomaine (PH);</li>\n      <li>Zudaw (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Academy of Breastfeeding Medicine Protocol Committee. ABM clinical protocol #9: use of galactogogues in initiating or augmenting the rate of maternal milk secretion (First Revision January 2011). <i>Breastfeed Med</i>. 2011;6(1):41-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/21332371/pubmed\" target=\"_blank\" id=\"21332371\">21332371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology. ACOG practice bulletin: nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2004;103(4):803-814.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/15051578/pubmed\" target=\"_blank\" id=\"15051578\">15051578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society of Anesthesiologists (ASA) Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. <i>Anesthesiology</i>. 2007;106(4):843-863.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/17413923/pubmed\" target=\"_blank\" id=\"17413923\">17413923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arvela P, Jouppila R, Kauppila A, et al. Placental transfer and hormonal effects of metoclopramide. <i>Eur J Clin Pharmacol</i>. 1983;24(3):345-348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/6407846/pubmed\" target=\"_blank\" id=\"6407846\">6407846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avery GB, Fletcher MA, MacDonald MG, eds. <i>Neontatology - Pathophysiology and Management of the Newborn</i>. 4th ed. J.B. Philadelphia, PA: Lippincott Company; 1994.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berkovitch M, Mazzota P, Greenberg R, et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. <i> Am J Perinatol</i>. 2002;19(6):311-316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/12357422/pubmed\" target=\"_blank\" id=\"12357422\">12357422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bylsma-Howell M, Riggs KW, McMorland GH, et al. Placental transport of metoclopramide: assessment of maternal and neonatal effects. <i>Can Anaesth Soc J</i>. 1983;30(5):487-492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/6354385/pubmed\" target=\"_blank\" id=\"6354385\">6354385</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chicella MF, Batres LA, Heesters MS, et al, &quot;Prokinetic Drug Therapy in Children: A Review of Current Options,&quot; <i>Ann Pharmacother</i>, 2005, 39(4):706-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/15755792/pubmed\" target=\"_blank\" id=\"15755792\">15755792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrari LR, Donlon JV. Metoclopramide reduces the incidence of vomiting after tonsillectomy in children. <i>Anesth Analg</i>. 1992;75(3):351-354.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/1510255/pubmed\" target=\"_blank\" id=\"1510255\">1510255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. <i>J Pediatr Gastroenterol Nutr</i>. 1986;5(4):556-559.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/3016226/pubmed\" target=\"_blank\" id=\"3016226\">3016226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furst SR1, Rodarte A. Prophylactic antiemetic treatment with ondansetron in children undergoing tonsillectomy. <i>Anesthesiology</i>. 1994;81(4):799-803.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/7943829/pubmed\" target=\"_blank\" id=\"7943829\">7943829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Meyer TA, Apfel CC, et al, &quot;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&quot; <i>Anesth Analg</i>, 2007, 105(6):1615-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/18042859/pubmed\" target=\"_blank\" id=\"18042859\">18042859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hansen WF, McAndrew S, Harris K, Z et al. Metoclopramide effect on breastfeeding the preterm infant: a randomized trial. <i>Obstet Gynecol</i>. 2005;105(2):383-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/15684169/pubmed\" target=\"_blank\" id=\"15684169\">15684169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ. Chemotherapy-induced nausea and vomiting. <i>N Engl J Med</i>. 2008;358(23):2482-2494.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/18525044/pubmed\" target=\"_blank\" id=\"18525044\">18525044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henzi I, Walder B, Tram&egrave;r MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. <i>Br J Anaesth</i>. 1999;83(5):761-771.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/10690140/pubmed\" target=\"_blank\" id=\"10690140\">10690140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauppila A, Arvela P, Koivisto M, et al. Metoclopramide and breast feeding: transfer into milk and the newborn. <i>Eur J Clin Pharmacol</i>. 1983;25(6):819-823.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/6662181/pubmed\" target=\"_blank\" id=\"6662181\">6662181</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, Butler HL, Lane JK, Carchman SH, Wright GJ. Metoclopramide pharmacokinetics and pharmacodynamics in infants with gastroesophageal reflux. <i>J Pediatr Gastroenterol Nutr</i>. 1988;7(6):823-829.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/3199269/pubmed\" target=\"_blank\" id=\"3199269\">3199269</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, van den Anker JN, Reed MD, et al, &quot;Pharmacokinetics of Metoclopramide in Neonates,&quot; <i>J Clin Pharmacol</i>, 1998, 38(2):122-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/9549642/pubmed\" target=\"_blank\" id=\"9549642\">9549642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimball AL, Carlton DP. Gastroesophageal reflux medications in the treatment of apnea in premature infants. <i>J Pediatr</i>. 2001;138(3):355-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/11241042/pubmed\" target=\"_blank\" id=\"11241042\">11241042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. <i>J Clin Oncol</i>. 2006;24(18):2932-2946.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/16717289/pubmed\" target=\"_blank\" id=\"16717289\">16717289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levichek Z, Atanackovic G, Oepkes D, et al. Nausea and vomiting of pregnancy. Evidence-based treatment algorithm. <i>Can Fam Physician</i>. 2002;48:267-268, 277.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/11889884/pubmed\" target=\"_blank\" id=\"11889884\">11889884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin DM, Furst SR, Rodarte A. A double-blinded comparison of metoclopramide and droperidol for prevention of emesis following strabismus surgery. <i>Anesthesiology</i>. 1992;76(3):357-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/1539845/pubmed\" target=\"_blank\" id=\"1539845\">1539845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. <i>Gastroenterology</i>. 2006;131(1):283-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/16831611/pubmed\" target=\"_blank\" id=\"16831611\">16831611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall G, Kerr S, Vowels M, O'Gorman-Hughes D, White L. Antiemetic therapy for chemotherapy-induced vomiting: metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone. <i>J Pediatr</i>. 1989;115(1):156-160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/2661789/pubmed\" target=\"_blank\" id=\"2661789\">2661789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Gorodischer R, Koren G, et al, &ldquo;The Safety of Metoclopramide Use in the First Trimester of Pregnancy,&rdquo; <i>N Engl J Med</i>, 2009, 360(24):2528-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/19516033/pubmed\" target=\"_blank\" id=\"19516033\">19516033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metoclopramide hydrochloride injection [prescribing information]. Irvine, CA: Teva Parenteral Medicines, Inc; November 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metoclopramide hydrochloride solution [prescribing information] .Baudette, MN: ANI Pharmaceuticals, Inc; March 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metozolv ODT (metoclopramide hydrochloride) [prescribing information]. Raleigh, NC: Salix Pharmaceuticals, Inc; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network&reg; (NCCN). Clinical Practice Guidelines in Oncology: Antiemesis. Version 1.2013. Available at http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quaynor H, Raeder JC. Incidence and severity of postoperative nausea and vomiting are aimilar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies. <i>Acta Anaesthesiol Scand</i>. 2002;46(1):109-113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/11903083/pubmed\" target=\"_blank\" id=\"11903083\">11903083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reglan (metoclopramide hydrochloride) [prescribing information]. Baudette, MN: ANI Pharmaceuticals, Inc; September 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rode H, Stunden RJ, Millar AJ, Cywes S. Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide. <i>J Pediatr Surg</i>. 1987;22(10):931-934.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/3681625/pubmed\" target=\"_blank\" id=\"3681625\">3681625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow R, Warr D, Molassiotis A. Antiemetics in children receiving chemotherapy. <i>Support Care Cancer</i>. 2005;13(2):129-131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/15538642/pubmed\" target=\"_blank\" id=\"15538642\">15538642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sankaran K, Yeboah E, Bingham WT, Ninan A. Use of metoclopramide in preterm infants. <i>Dev Pharmacol Ther</i>. 1982;5(3-4):114-119.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/7151642/pubmed\" target=\"_blank\" id=\"7151642\">7151642</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith I, Kranke P, Murat I, et al. European Society of Anaesthesiology. Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology. <i>Eur J Anaesthesiol</i>. 2011;28(8):556-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/21712716/pubmed\" target=\"_blank\" id=\"21712716\">21712716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&oslash;rensen HT, Nielsen GL, Christensen K, et al. Birth outcome following maternal use of metoclopramide. The Euromap study group. <i>Br J Clin Pharmacol</i>. 2000;49(3):264-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/10718782/pubmed\" target=\"_blank\" id=\"10718782\">10718782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrin BN, McWilliams NB, Maurer HM. Side effects of metoclopramide as an antiemetic in childhood cancer chemotherapy. <i>J Pediatr</i>. 1984;104(1):138-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/6690659/pubmed\" target=\"_blank\" id=\"6690659\">6690659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tolia V, Calhoun J, Kuhns L, Kauffman RE. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. <i>J Pediatr</i>. 1989;115(1):141-145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/2661788/pubmed\" target=\"_blank\" id=\"2661788\">2661788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). <i>J Pediatr Gastroenterol Nutr</i>. 2009;49(4):498-547.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/19745761/pubmed\" target=\"_blank\" id=\"19745761\">19745761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuppa AA, Sindico P, Orchi C, Carducci C, Cardiello V, Romagnoli C. Safety and efficacy of galactogogues: substances that induce, maintain and increase breast milk production. <i>J Pharm Pharm Sci</i>. 2010;13(2):162-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metoclopramide-pediatric-drug-information/abstract-text/20816003/pubmed\" target=\"_blank\" id=\"20816003\">20816003</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12602 Version 218.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8117624\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195600\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195601\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060336\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443886\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060329\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195570\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F195554\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8083407\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060340\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F195592\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060339\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195664\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195661\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195578\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195558\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F195649\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195563\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195566\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195581\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060335\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195557\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F195577\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F195580\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195583\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12602|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metoclopramide-drug-information\" class=\"drug drug_general\">Metoclopramide: Drug information</a></li><li><a href=\"topic.htm?path=metoclopramide-patient-drug-information\" class=\"drug drug_patient\">Metoclopramide: Patient drug information</a></li></ul></div></div>","javascript":null}